Dupilumab is a fully human monoclonal antibody against theIL4 receptor alpha subunit and blocks the action of both IL4 and IL13. It hasshown great potential in the treatment of severe eosinophilic asthma, as wellas in other conditions such as nasal polyposis. However, its use in lungtransplantation (LuTx) has not been described yet. We present the use ofdupilumab in a LuTx recipient, who suffered an asthma relapse shortly aftersurgery.
Use of Dupilumab in Asthma Relapse After Lung Transplant / A. Buscemi, L. Morlacchi, V. Rossetti, M. Cavallini, A. Palleschi, L. Rosso, M. Mantero, M. Nosotti, F. Blasi. ((Intervento presentato al 44. convegno ISHLT Annual Meeting & Scientific Sessions tenutosi a Praha nel 2024.
Use of Dupilumab in Asthma Relapse After Lung Transplant
A. BuscemiPrimo
;L. MorlacchiSecondo
;A. Palleschi;L. Rosso;M. Mantero;M. NosottiPenultimo
;F. BlasiUltimo
2024
Abstract
Dupilumab is a fully human monoclonal antibody against theIL4 receptor alpha subunit and blocks the action of both IL4 and IL13. It hasshown great potential in the treatment of severe eosinophilic asthma, as wellas in other conditions such as nasal polyposis. However, its use in lungtransplantation (LuTx) has not been described yet. We present the use ofdupilumab in a LuTx recipient, who suffered an asthma relapse shortly aftersurgery.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ISHLT 2024 (Use of Dupilumab...).pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
180.65 kB
Formato
Adobe PDF
|
180.65 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
